These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17886338)

  • 41. [Immunopathogenesis of HCV infection].
    Kanto T
    Nihon Rinsho; 2011 May; 69 Suppl 4():86-91. PubMed ID: 22096899
    [No Abstract]   [Full Text] [Related]  

  • 42. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
    Fujii S
    Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasmacytoid dendritic cells move down on the list of suspects: in search of the immune pathogenesis of chronic hepatitis C.
    Albert ML; Decalf J; Pol S
    J Hepatol; 2008 Dec; 49(6):1069-78. PubMed ID: 18929418
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Molecular mechanisms for suppression of TLR signaling pathway by virus infection].
    Fujii N; Yokota S; Yokosawa N; Okabayashi T
    Tanpakushitsu Kakusan Koso; 2008 May; 53(6):710-9. PubMed ID: 18453146
    [No Abstract]   [Full Text] [Related]  

  • 45. Dendritic cells and innate defense against tumor cells.
    Ullrich E; Ménard C; Flament C; Terme M; Mignot G; Bonmort M; Plumas J; Chaperot L; Chaput N; Zitvogel L
    Cytokine Growth Factor Rev; 2008 Feb; 19(1):79-92. PubMed ID: 18155952
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased frequency of CD56Bright NK-cells, CD3-CD16+CD56- NK-cells and activated CD4+T-cells or B-cells in parallel with CD4+CDC25High T-cells control potentially viremia in blood donors with HCV.
    Zarife MA; Reis EA; Carmo TM; Lopes GB; Brandão EC; Silva HR; Santana N; Martins-Filho OA; Reis MG
    J Med Virol; 2009 Jan; 81(1):49-59. PubMed ID: 19031471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The current immune function of hepatic dendritic cells.
    Hsu W; Shu SA; Gershwin E; Lian ZX
    Cell Mol Immunol; 2007 Oct; 4(5):321-8. PubMed ID: 17976311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acute hepatitis C virus infection: a chronic problem.
    Blackard JT; Shata MT; Shire NJ; Sherman KE
    Hepatology; 2008 Jan; 47(1):321-31. PubMed ID: 18161707
    [No Abstract]   [Full Text] [Related]  

  • 49. New insights into the immunopathogenesis of chronic hepatitis C.
    Diepolder HM
    Antiviral Res; 2009 Jun; 82(3):103-9. PubMed ID: 19428600
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blocking of monocyte-associated B7-H1 (CD274) enhances HCV-specific T cell immunity in chronic hepatitis C infection.
    Jeong HY; Lee YJ; Seo SK; Lee SW; Park SJ; Lee JN; Sohn HS; Yao S; Chen L; Choi I
    J Leukoc Biol; 2008 Mar; 83(3):755-64. PubMed ID: 18086898
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Do direct acting antivirals cure chronic hepatitis C?
    Jakobsen JC; Nielsen EE; Koretz RL; Gluud C
    BMJ; 2018 May; 361():k1382. PubMed ID: 29748173
    [No Abstract]   [Full Text] [Related]  

  • 52. Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro.
    Helbig KJ; Ruszkiewicz A; Lanford RE; Berzsenyi MD; Harley HA; McColl SR; Beard MR
    J Virol; 2009 Jan; 83(2):836-46. PubMed ID: 18987152
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Decreased expressions of CD1d molecule on liver dendritic cells in subcutaneous tumor bearing mice.
    Tatsumi T; Takehara T; Yamaguchi S; Sasakawa A; Yamamoto M; Fujita Y; Miyagi T; Ohkawa K; Hayashi N
    J Hepatol; 2008 Nov; 49(5):779-86. PubMed ID: 18760855
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interfering with interferons: Hepatitis C virus counters innate immunity.
    Freundt EC; Lenardo MJ
    Proc Natl Acad Sci U S A; 2005 Dec; 102(49):17539-40. PubMed ID: 16314558
    [No Abstract]   [Full Text] [Related]  

  • 55. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
    Fujii S; Shimizu K; Hemmi H; Steinman RM
    Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Update on natural killer cells: cross-talk with dendritic cells and role in the cure of acute myeloid leukemias.
    Moretta L; Ferlazzo G; Mingari MC; Melioli G; Moretta A
    Cancer J; 2003; 9(4):232-7. PubMed ID: 12967130
    [No Abstract]   [Full Text] [Related]  

  • 57. Cytokines as a link between innate and adaptive antitumor immunity.
    Belardelli F; Ferrantini M
    Trends Immunol; 2002 Apr; 23(4):201-8. PubMed ID: 11923115
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Do lambda-IFNs IL28A and IL28B act on human natural killer cells?
    Krämer B; Eisenhardt M; Glässner A; Körner C; Sauerbruch T; Spengler U; Nattermann J
    Proc Natl Acad Sci U S A; 2011 Aug; 108(34):E519-20; author reply E521-2. PubMed ID: 21825163
    [No Abstract]   [Full Text] [Related]  

  • 59. [Innate immunity in chronic viral hepatitis].
    Tatsumi T; Takehara T
    Nihon Shokakibyo Gakkai Zasshi; 2013 May; 110(5):764-71. PubMed ID: 23648529
    [No Abstract]   [Full Text] [Related]  

  • 60. Cell-mediated cytotoxicity against human tumors: lessons learned and future prospects.
    Herberman RB; Oldham RK
    J Biol Response Mod; 1983; 2(2):111-20. PubMed ID: 6196451
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.